EFSA novel food roundup — May 2026

EFSA's register tells you what happened last month. It does not tell you what each new applicant is walking into. Our first monthly roundup: May's novel food activity, every dossier read against the bar its category has to clear.

Every month, EFSA's public register turns over: new dossiers arrive, others clear validation, and a handful of opinions are published. The register tells you what happened. It does not tell you what each new applicant is walking into.

That second column is the one we add. For every dossier that arrived in May, we know how products in the same category have fared across 239 prior opinions — the implied bar we measured in *What EFSA really checks*. This is the first Borgh roundup: the month's novel food activity, each item read against the precedent it faces.

May 2026, in numbers

Across the Novel Foods domain, the register recorded 8 new dossiers received, 3 applications validated into risk assessment, and 5 opinions published — alongside several Article 4 novelty determinations settled by the European Commission. All of it is public the moment it happens. What follows is that record, read through the lens of what came before.

The bar each new dossier walks into

Two of May's eight arrivals are microalgal: a modification to an authorised *Schizochytrium* oil, and *TetraSOL*, an extract of the microalga *Tetradesmus obliquus*. Microalgae is not an easy category. Across 17 prior microalgal opinions in our data, 29% ended non-favourably — well above the 18% baseline across all novel foods — and the recurring sticking points are contaminant characterisation and batch consistency. An applicant who has not closed those two questions is walking toward the most common reason microalgal dossiers stall.

A third arrival — *Weissella cibaria* CMU — is a microbial novel food. Microbial and fermentation cases reject less often in our data (around 9% of 11), but they clock-stop more than almost any category: the panel's questions cluster on strain identity and the safety of the production organism, and are rarely resolved in the first round.

The rest span a vitamin D2 mushroom powder (vitamin and mineral forms reject rarely — 8% — but live or die on specification and bioavailability), a steviol derivative, a coded substance, and two traditional-food notifications — yaupon holly and cacay-nut flour — which take the shorter notification route rather than a full application.

The point is not to predict any single outcome. It is that before a line of the dossier is read, the category already tells you where the panel will push hardest.

What cleared validation — and how fast

Three applications passed validation in May. The validation gap — submission to the clock starting — is a quiet signal of dossier quality in its own right:

- Defatted Passion Fruit Seed Extract — about 7 months from submission - Gamma-aminobutyric acid (GABA) — about 6 months - A modification to Xia Powder 435 — about 2.5 months

A modification clears faster than a first-time application, as you would expect. The first-time extracts took the better part of a year just to be accepted as complete — before the scientific assessment even begins.

Five opinions, and the categories behind them

Five opinions were published, including one on a cannabidiol (CBD) isolate. CBD is worth watching: it is the worst-performing category in our entire dataset — all four prior CBD opinions we hold ended non-favourably, and published CBD applications have spent years in assessment. A new CBD opinion is rarely good news for the applicant.

Also published: a DHA-rich oil from *Schizochytrium* — the same microalgal category flagged above — and opinions on an L-alpha-GPC, a peptide mixture, and beta-nicotinamide mononucleotide (β-NMN), the longevity ingredient.

Novelty, settled

Separately, the European Commission resolved several Article 4 consultations — whether a food even counts as novel. Two matter for applicants: S-adenosyl-L-methionine and **peanut (*Arachis hypogaea*) protein were both determined novel**, meaning they need authorisation before sale. Three botanicals — including olive (*Olea europaea*) — were confirmed not novel. Novelty is the cheapest question to get wrong: a year of dossier work can rest on an answer a short consultation would have settled.

How to read this

The events above — received, validated, published, determined — are EFSA's and the European Commission's own public records, pulled directly from their registers. The implied bar attached to each category is Borgh's analysis of 239 published opinions: the share that ended non-favourably, and the deficiencies the panels raised most often. That is our reading of the precedent, not an official EFSA classification, and where the sample is small — CBD rests on four opinions — we say so. Treat the percentages as well-grounded direction, not decimals.

What no register shows you is that second column: not just that a microalgal dossier arrived, but what microalgal dossiers keep getting stopped for. That is the column we add.

Sources

- EFSA Register of Questions (Novel Foods domain) — dossier receipt, validation, and opinion publication dates, retrieved June 2026. - European Commission Novel Food Catalogue — Article 4 novelty determinations. - Borgh structured analysis of 239 published EFSA opinions (2003–2026); baseline non-favourable rate 18% (N=239). Method in *What EFSA really checks*.